

Study of the DNA-methylation status in primary breast cancer using bioinformatics and methylation specific PCR

Thesis

Submitted for Partial Fulfillment for the Requirement of
M.D. Degree in Basic Science (Medical Biochemistry)

By

Marwa Mahmoud Abd el Hamied

Assistant lecturer of medical biochemistry and molecular biology
Faculty of Medicine – Ain shams University

Under supervision of

Prof. Dr. / Samar Kamal Kasem

Professor of medical biochemistry and molecular biology
Faculty of medicine-Ain shams university

Porf.Dr. / Maged Ramadan Abo Seada

Professor of Obstetrics and Gynecology
Faculty of medicine-Ain shams university

Porf.Dr. / Dr. Maha Mohamed Sallam

Professor of medical biochemistry and molecular biology
Faculty of medicine-Ain shams university

Ass Prof. / Hanan Hussien Shehata

Assistant Professor of medical biochemistry and molecular biology
Faculty of Medicine – Ain shams University

Ain Shams University
Faculty of Medicine.
2009

دراسة اضافة مجموعة الميثيل الي الحمض النووي في حالة سرطان الثدي الأولية باستخدام برنامج تقنية المعلومات الحيوية و تفاعل البلمرة المتسلل باضافة مجموعة الميثيل

رسالة مقدمة توطئة للحصول على درجة الدكتوراة فى الكيمياء الحيوية

مقدمة من

الطبيبة/ مروة محمود عبد الحميد

مدرس مساعد بقسم الكيمياء الحيوية الطبية
كلية الطب – جامعة عين شمس

تحت إشراف

أ.د/ سمر كمال قاسم

أستاذ الكيمياء الحيوية الطبية و البيولوجيا الجزيئية
كلية الطب – جامعة عين شمس

أ.د/ ماجد رمضان أبو سعدة

أستاذ أمراض النساء و التوليد
كلية الطب – جامعة عين شمس

أ.د / مها محمد سلام

أستاذ الكيمياء الحيوية الطبية و البيولوجيا الجزيئية
كلية الطب – جامعة عين شمس

أ.م / حنان حسين شحاتة

أستاذ مساعد الكيمياء الحيوية الطبية و البيولوجيا الجزيئية
كلية الطب – جامعة عين شمس

جامعة عين شمس

كلية الطب

٢٠٠٩

List of Contents

Title	Page
List of Abbreviations	i
List of Figures	iv
List of Tables	vii
Introduction and Aim of the Work	1-5
I. Review of Literature	6
Breast cancer.....	6
Epidemiology of Breast cancer.....	6
Recognized Risk Factors For The Development Of Breast Cancer.....	10
1. Aging	10
2. Race and ethnicity	10
3. Risk factors related to estrogen exposure	11
Menstrual periods	11
Parity.....	11
Recent oral contraceptive use	12
Breast feeding.....	12
4. Family History and Breast Cancer Risk.....	13
5. Genetic risk factors.....	13
6. Lifestyle-related factors and breast cancer risk....	15
Alcohol intake.....	15
Tobacco smoking.....	16
Overweight or obesity.....	16
The American Joint Committee on Cancer (AJCC)	17
The TNM staging system	17
Breast cancer stage grouping.....	19
Histopathological Grading of Breast Cancer.....	23
Estrogen and progesterone receptor status.....	25

List of Contents (Cont.)

Title	Page
Human Epidermal Growth Factor Receptor 2	26
Molecular Subtypes of Breast Cancer.....	26
DNA methylation	31
Epigenetics.....	31
CpG islands.....	35
DNA methylation machinery	36
1. DNA Methyltransferases (DNMTs).....	36
2. Methyl-binding domain (MBD) proteins	38
Mechanisms of DNA Methylation-mediated transcriptional repression.....	39
Aberrant DNA Methylation and Cancer.....	43
Hypomethylation	45
Retro-transposon activation.....	46
Oncogene activation	46
CpG island hypermethylation in tumor suppressor gene	47
Potential Role of Promotor Hypermethylation as Tumour Markers.....	49
Methods for DNA Methylation Analysis.....	49
Hypermethylation Profiles in Different Types of Human Cancer.....	61
Mucin 1 gene.....	64

List of Contents (Cont.)

Title	Page
Heparan sulfate 3-O-sulfotransferase gene.....	68
Bioinformatics	72
III. Subjects and Methods	78
IV. Results	114
V. DISCUSSION	144
VI. Summary and Conclusion	159
VII References	167-191
VIII. Arabic Summary	---

List of Abbreviations

AJCC	American Joint Committee on Cancer
ALL	Acute lymphoblastic leukemia
APC	Adenomatous Polyposis Coli
ATM	Ataxia telangiectasia mutated
BCL-2	B-cell leukemia/lymphoma
BRCA1	Breast cancer 1
BRIP1	BRCA1 interacting protein C-terminal helicase 1
BTB	BCL6(B-cell lymphoma 6 protein) forms a tightly intertwined butterfly-shaped homodimer
β-Catenin	Beta-cadherin-associated protein
CDH1	Cadherin 1, type 1, E-cadherin
CDKs	Cyclin-dependent kinases
CHEK2	Checkpoint homolog
CIN	Chromosome instability
CIS	Carcinoma in situ
<i>c-myc</i>	Cellular-myelocytomatosis. A transcription factor
CpG	Cytosine (phosphate) Guanine
CRBP	Cytoplasmic retinol binding protein
CRC	Colorectal cancer
CTNNB1	Catenin (cadherin-associated protein), beta 1
DCIS	Ductal carcinoma in situ
DNMTs	DNA methyltransferases
EB1	End-binding 1 protein
E-cadherin	Epithelial - Calcium dependent adhesion molecules
EGFR	Endothelial growth factor receptor
ELISA	Enzyme-linked immunosorbent assay
ECM	Extracellular matrix

ER	Estrogen receptors
HDAC	Histone Deacetylase enzymes
HDLG	Human disc large protein
HER2	Human Epidermal Growth Factor Receptor 2
HPLC	High performance liquid chromatography
HPV	Human Papilloma Virus
HS3ST2	Heparan sulfate 3-O-sulfotransferase gene
HSulf	Heparan sulfotransferase
HSPGs	Heparan sulfate proteoglycans
IBC	Inflammatory breast cancer
Kaiso	Zinc finger and BTB domain-containing protein 33
LCIS	Lobular carcinoma in situ
MAGE	The melanoma antigen gene
MAPK	Mitogen-activated protein kinase
Mc-MSP	melting-curve analysis
MBPs	Methyl-CpG binding proteins
MBD	Methyl-CpG binding domain proteins
MeCP2	Methyl CpG binding protein 2
MGMT	Methylguanine-DNA methyltransferase,
MI	Methylation index
MS-PCR	Methylation specific PCR
MS-RDA	Methylation-sensitive representational difference analysis
Muc1	Mucin1 gene
NPV	Negative predictive value
NSCLC	Non-small-cell lung cancer
NuRD	The nucleosome remodelling and histone deacetylase complex

OSCC	Oral squamous cell carcinoma
PALB2	Partner and localizer of BRCA2
PBS	Phosphate buffer saline
PMA	Percentage of methylation allele
PMF-1	Polyamine modulated factor-1
POZ	Pox virus and Zinc finger
PPV	Positive predictive value
PR	Progesterone receptors
PTP-BL	Protein tyrosine phosphatase, non-receptor type 13
PTEN	Phosphatase and tensin homolog
QMSP	Quantitative Methylation Specific PCR
RARbeta2	Retinoic acid receptor, beta
RASSF1A	Ras association domain family member 1A
Rb	Retinoblastoma gene
RLGS-M	Restriction Landmark Genomic Scanning for Methylation
SCC	Squamous cell carcinoma
SPSS	Statistical Package for the Social Sciences
STS	Soft tissue sarcoma
TA	Telomerase activity
TBE buffer	Trisma, Boric and EDTA
Tcf	T-cell factor
TIMPs	Tissue inhibitors of matrix metalloproteinase
TNM	Tumor, lymph node, and metastasis
TP1	Telomerase associated protein
TP53	Tumor protein p53

List of figures

Title	Page
Figure (1): Age-Standardized Breast Cancer Incidence and Mortality Rates.	7
Figure (2): The two main components of epigenetics.	32
Figure (3): DNA Methylation Reaction Catalyzed by DNA Methyltransferase.	34
Figure (4): Mechanisms of DNA Methylation-mediated Transcriptional Repression.	42
Figure (5): Possible roles of increased CpG islands and decreased global DNA methylation in tumour development.	44
Figure (6): A CpG island hypermethylation profile of human cancer. <i>Y</i> -axis, frequency of hypermethylation for each gene in each primary.	63
Figure (7): Functional significance of cell surface HSPGs.	69
Figure (8): Bioinformatics science.	73
Figure (9): The concept lattice of hyper-methylated genes in breast cancer subtypes.	81
Figure (10): The concept lattice of hypo-methylated genes in breast cancer subtypes.	83
Figure (11): Structure of Silica-Gel Materials.	88

List of figures

<u>Title</u>	<u>Page</u>
Figure (12): Step 1: Sulphonation; Step 2: hydrolytic deamination and Step 3: alkali-desulphonation.	95
Figure (13): Illustration of band quantitation by Quantity one computer program version 4.6.3	110
Figure (14): Methylation-specific PCR product analysis of malignant breast tissue <i>Muc1</i> gene by agarose gel electrophoresis and ethidium bromide staining.	116
Figure (15): Methylation-specific PCR product analysis of benign and normal breast tissue <i>Muc1</i> gene by agarose gel electrophoresis and ethidium bromide staining.	117
Figure (16): Positivity Rate of Muc1 gene methylation as measured by MS-PCR in breast tissue samples of different groups of study.	122
Figure (17): Methylation-specific PCR product analysis of breast cancer tissue <i>HS3ST2</i> gene by agarose gel electrophoresis and ethidium bromide staining.	125
Figure (18): Methylation-specific PCR product analysis of benign and normal breast tissue <i>HS3ST2</i> gene by agarose gel electrophoresis and ethidium bromide staining.	126

Figure (19):	Positivity Rate of <i>HS3ST2</i> gene methylation as measured by MS-PCR in breast tissue samples of different groups of study.	131
Figure (20):	ROC curve analysis for the percentage of methylated alleles (PMA) of <i>Muc1</i> gene.	137
Figure (21):	ROC curve analysis for the percentage of methylated alleles (PMA) of <i>HS3ST2</i> gene.	142

List of Tables

Title	Page
Table (1): Breast cancer T, N and M categories.	18
Table (2): New Breast cancer TNM staging combinations.	23
Table (3): Scarff-Bloom-Richardson Grade System.	24
Table (4): Examples of genes exhibiting hyper-methylation in cancer.	48
Table (5): Hypermethylated genes in breast cancer subtypes based on DNA methylation-based microarray analysis.	80
Table (6): Hypomethylated genes in breast cancer subtypes based on DNA methylation-based microarray analysis.	82
Table (7): <i>Muc1</i> primers used in MS-PCR analysis.	103
Table (8): <i>HS3ST2</i> primers used in MS-PCR analysis.	104
Table (9): Age in different groups of the study (in years).	115
Table (10): Pattern of <i>Muc1</i> methylation in the different groups of the study (n = 60).	119
Table (11): Pattern of <i>Muc1</i> gene methylation in both the control and malignant groups of the study.	120
Table (12): Pattern of <i>Muc1</i> gene methylation in luminal A and luminal B subtypes of malignant groups of the study (n = 30).	121
Table (13): The relation of <i>Muc1</i> gene methylation status to different clinico-pathological factors in breast cancer.	123

List of Tables

<u>Title</u>	<u>Page</u>
Table (14): Pattern of <i>HS3ST2</i> methylation in the different groups of the study.	128
Table (15): Pattern of <i>HS3ST2</i> gene methylation in the control and malignant groups of the study.	129
Table (16): Pattern of <i>HS3ST2</i> gene methylation in luminal A and B subtypes of malignant groups of the study.	130
Table (17): The relation of <i>HS3ST2</i> gene methylation status to different clinico-pathological factors in breast cancer.	132
Table (18): Quantitative MSP presented as PMA of <i>Muc1</i> gene and positivity rate in the malignant group compared to benign and normal control groups.	136
Table (19): The performance characteristics of the positivity of <i>Muc1</i> gene unmethylation in breast tissue.	137
Table (20): PMA of <i>Muc1</i> gene and its positivity rates in relation to different clinico-pathological factors of breast cancer.	138
Table (21): Quantitative MSP presented as PMA of <i>HS3ST2</i> gene and positivity rate in the malignant group compared to benign and normal control groups.	141

Table (22):	The performance characteristics of the positivity of <i>HS3ST2</i> gene methylation in breast tissue.	142
Table (23):	PMA of <i>HS3ST2</i> gene and its positivity rates in relation to different clinico-pathological factors of breast cancer.	143